Loading
A phase 3 trial of Tamoxifen and Triptorelin in Breast cancer, run by ETOP IBCSG Partners Foundation, completed.
Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer is a phase 3 interventional study registered as NCT00066703 by ETOP IBCSG Partners Foundation, with 2672 participants recorded, started 2003-11-03 and reaching its primary completion in 2011-03-11. Interventions recorded: exemestane, tamoxifen, triptorelin. Conditions recorded: Breast Cancer.
Linked to the drug Triptorelin because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
2,672 enrolled.
95% CI 85.7 to 88.7; Figures from the ClinicalTrials.gov results section (first posted 2016-04-05), not from a publication · 95% CI 89.7 to 92.3
Source95% CI 92.1 to 94.3; Figures from the ClinicalTrials.gov results section (first posted 2016-04-05), not from a publication · 95% CI 92.2 to 94.4
SourceShares Triptorelin, Tamoxifen, Breast cancer (all types) and the tag pipeline.
Shares Triptorelin and the tag pipeline.
Shares Tamoxifen, Breast cancer (all types) and the tag pipeline.
Shares Triptorelin and the tag pipeline.
Shares Tamoxifen, Breast cancer (all types) and the tag pipeline.
Shares Tamoxifen, Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.